

# MARKET REPORT



Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) - Analysis, Share, Trends, Size, & Forecast from 2020 - 2026- COVID-19 Updated

**BioPortfolio**

Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



**AnalystView**  
Market Insights

# Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

## REPORT HIGHLIGHT

Liver cancer drugs market was valued at USD 630.1 million by 2019, growing with 16.4% CAGR during the forecast period, 2020-2026

## Market Dynamics

Liver cancer is estimated to be the fifth most prevalent cancer and accounts for about 9.0% of all cancer deaths across the globe. In 2012, around 782,451 novel cases of liver cancer were diagnosed, of which 745,533 deaths were reported due to the life-threatening disease. Primary liver cancer remains a significant public health issue owing to poor survival rate and its extremely aggressive nature. Hepatocellular carcinoma is one of the most common types of liver cancer that begins in the hepatocyte, which is the main type of liver cell.

The growing prevalence of liver cancer, government initiatives to increase cancer awareness, and increasing investments in R&D activities to develop novel therapies are the major factors driving the growth of global liver cancer drugs market. In addition, the large amount of the population is exposed to certain risk factors contributing to liver cancer owing to the growing adoption of unhealthy lifestyle by people. Also, heavy consumption of alcohol and tobacco smoking are the encouraging factors for liver cancer. Thus, the above-mentioned factors will propel the market growth during the forecast period. The estimations by the American Cancer Society states that there would be around 42,810 novel cases of liver cancer in the U.S. by the end of 2020. Moreover, the rising demand for therapeutic drugs for the treatment of liver cancer is likely to create lucrative opportunities in the global industry. However, a dearth in the number of donors and the diagnosis of disease in the advanced stage with no feasibility of transplantation or surgery is predicted to restrict the market growth in the coming future.

## Therapeutic Class Takeaway

The immunotherapy segment is anticipated to generate the majority of share in the global market owing to increasing R&D investments and the launch of novel drugs for treating liver cancer. If patients have an adequate reserve for hepatic function, the optimal treatment for HCC is a partial surgical resection. The resection of cirrhotic livers can grow the risk of liver failure which is a fatal complication. However, the resection rates have improved hugely after resection over the past few decades. On the other hand, the relapse rates are very high for after surgical resection. In the treatment of HCC, most of the systemic drugs have minimal efficacy, and thus R&D is primarily focused on hepatocarcinogenesis.

The HCC or hepatocellular carcinoma is the most common form of liver cancer. HCC mostly occurs in people who are suffering from chronic liver diseases such as cirrhosis. It is also one of the major causes of cancer-related deaths all across the globe. It is observed that the African and Asian countries have higher prevalence rates of hepatocellular carcinoma as compared to the developed economies. This is majorly owing to the disparity in the main risk factors causing HCC such as hepatitis B and C virus infection in these regions. With the rise in the occurrence of hepatocellular carcinoma, there is projected to be a huge demand for liver cancer drugs. Hence, the growing prevalence of cancer and the rise in unmet medical needs are the significant factors driving the segmental market growth of HCC during the period of forecast.

## Regional Takeaway

Presently, the North America region is dominating the market owing to the growing geriatric population and the presence of well-established healthcare infrastructure in this region. On the other hand, the Asia Pacific market for liver cancer drugs will grow at a notable rate owing to the higher prevalence rates of HCC than other regions in the world.

Key vendors of the market include:

- Merck
- Bristol-Myers Squibb
- Bayer
- Eisai
- Exelixis
- Ono Pharmaceutical
- Onyx Pharmaceuticals Inc
- Alnylam Pharmaceuticals, Inc
- Pfizer Inc
- F. Hoffmann-La Roche Ltd.

The market size and forecast for each segment and sub-segments has been considered as below:

- Historical Year - 2015 to 2018
- Base Year - 2019
- Estimated Year - 2020
- Projected Year - 2026

## TARGET AUDIENCE

- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors

## SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

### GLOBAL LIVER CANCER DRUGS MARKET, BY THERAPEUTIC CLASS

- Immunotherapy

□ Targeted Therapy

#### GLOBAL LIVER CANCER DRUGS MARKET, BY TYPE

□ Hepatoblastoma

□ Hepatocellular Carcinoma

□ Cholangio Carcinoma

□ Others

#### GLOBAL LIVER CANCER DRUGS MARKET, BY REGION

□ North America

o The U.S.

o Canada

□ Europe

o Germany

o France

o Italy

o Spain

o United Kingdom

o Rest of Europe

□ Asia Pacific

o India

o China

o South Korea

o Japan

o Singapore

o Rest of APAC

□ Latin America

o Brazil

o Mexico

o Argentina

o Rest of LATAM

□ Middle East and Africa

o Saudi Arabia

o United Arab Emirates

o Rest of MEA

## Additional Details

**Publisher** : AnalystView

**Reference** : AV86

**Number of Pages** : 165

**Report Format** : PDF

**Publisher Information** :



AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

# Table Of Contents for Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

- TABLE OF CONTENT1. LIVER CANCER DRUGS MARKET OVERVIEW1.1. Study Scope1.2. Assumption and Methodology 2. EXECUTIVE SUMMARY2.1. Market Snippet2.1.1. Market Snippet by Therapeutic Class2.1.2. Market Snippet by Type2.1.3. Market Snippet by Region2.2. Competitive Insights3. LIVER CANCER DRUGS KEY MARKET TRENDS3.1. Market Drivers 3.1.1. Impact Analysis of Market Drivers3.2. Market Restraints3.2.1. Impact Analysis of Market Restraints3.3. Market Opportunities3.4. Market Future Trends4. LIVER CANCER DRUGS INDUSTRY STUDY4.1. Porter’s Five Forces Analysis4.2. Marketing Strategy Analysis4.3. Growth Prospect Mapping4.4. Regulatory Framework Analysis4.5. COVID-19 Impact Analysis4.5.1. Pre-COVID-19 Impact Analysis4.5.2. Post-COVID-19 Impact Analysis5. LIVER CANCER DRUGS MARKET LANDSCAPE5.1. Market Share Analysis5.2. Key Innovators5.3. Breakdown Data, by Key manufacturer5.3.1. Established Player Analysis5.3.2. Emerging Player Analysis6. LIVER CANCER DRUGS MARKET – BY THERAPEUTIC CLASS6.1. Overview6.1.1. Segment Share Analysis, By Therapeutic Class, 2019 & 2026 (%)6.2. Targeted Therapy6.2.1. Overview6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)6.3. Immunotherapy6.3.1. Overview6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)6.4. Others6.4.1. Overview6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)7. LIVER CANCER DRUGS MARKET – BY TYPE7.1. Overview7.1.1. Segment Share Analysis, By Type, 2019 & 2026 (%)7.2. Hepatoblastoma7.2.1. Overview7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)7.3. Hepatocellular Carcinoma7.3.1. Overview7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)7.4. Cholangio Carcinoma7.4.1. Overview7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)7.5. Others7.5.1. Overview7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8. LIVER CANCER DRUGS MARKET- BY GEOGRAPHY8.1. Introduction8.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)8.2. North America8.2.1. Overview8.2.2. Key Manufacturers in North America 8.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US\$ Million)8.2.4. North America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US\$ Million)8.2.5. North America Market Size and Forecast, By Type, 2015 - 2026 (US\$ Million)8.2.6. U.S.8.2.6.1. Overview8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.2.7. Canada8.2.7.1. Overview8.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.3. Europe8.3.1. Overview8.3.2. Key Manufacturers in Europe8.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US\$ Million)8.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US\$ Million)8.3.5. Europe Market Size and Forecast, By Type, 2015 - 2026 (US\$ Million)8.3.6. Germany8.3.6.1. Overview8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.3.7. Italy8.3.7.1. Overview8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.3.8. United Kingdom8.3.8.1. Overview8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.3.9. France8.3.9.1. Overview8.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.3.10. Rest of Europe8.3.10.1. Overview8.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.4. Asia Pacific (APAC)8.4.1. Overview8.4.2. Key Manufacturers in Asia Pacific8.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US\$ Million)8.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US\$ Million)8.4.5. Asia Pacific Market Size and Forecast, By Type, 2015 - 2026 (US\$ Million)8.4.6. India8.4.6.1. Overview8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.4.7. China8.4.7.1. Overview8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.4.8. Japan8.4.8.1. Overview8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.4.9. South Korea8.4.9.1. Overview8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.4.10. Rest of APAC8.4.10.1. Overview8.4.10.2. Market Analysis, Forecast, and Y--

-Y Growth Rate, 2015 - 2026, (US\$ Million)8.5. Latin America8.5.1. Overview8.5.2. Key Manufacturers in Latin America8.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US\$ Million)8.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US\$ Million)8.5.5. Latin America Market Size and Forecast, By Type, 2015 - 2026 (US\$ Million)8.5.6. Brazil8.5.6.1. Overview8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.5.7. Mexico8.5.7.1. Overview8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.5.8. Argentina8.5.8.1. Overview8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.5.9. Rest of LATAM8.5.9.1. Overview8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.6. Middle East and Africa8.6.1. Overview8.6.2. Key Manufacturers in Middle East and Africa8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US\$ Million)8.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US\$ Million)8.6.5. Middle East and Africa Market Size and Forecast, By Type, 2015 - 2026 (US\$ Million)8.6.6. Saudi Arabia8.6.6.1. Overview8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)8.6.7. United Arab Emirates8.6.7.1. Overview8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US\$ Million)9. KEY VENDOR ANALYSIS9.1. Merck9.1.1. Company Snapshot9.1.2. Financial Performance9.1.3. Product Benchmarking 9.1.4. Strategic Initiatives 9.2. Bristol-Myers Squibb9.3. Bayer9.4. Eisai9.5. Exelixis9.6. Onyx Pharmaceuticals Inc9.7. Alnylam Pharmaceuticals, Inc9.8. Pfizer Inc9.9. F. Hoffmann-La Roche Ltd.10. 360 DEGREE ANALYSTVIEW11. APPENDIX11.1. Research Methodology11.2. References11.3. Abbreviations11.4. Disclaimer11.5. Contact Us



# List Of Tables in Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

## List of Tables

TABLE List of data sources

TABLE Market drivers; Impact Analysis

TABLE Market restraints; Impact Analysis

TABLE Liver Cancer Drugs market: Therapeutic Class Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class

TABLE Global Liver Cancer Drugs market, by Therapeutic Class 2015-2026 (USD Million)

TABLE Liver Cancer Drugs market: Type Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Type

TABLE Global Liver Cancer Drugs market, by Type 2015-2026 (USD Million)

TABLE Liver Cancer Drugs market: Regional snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Region

TABLE Global Liver Cancer Drugs market, by Region 2015-2026 (USD Million)

TABLE North America Liver Cancer Drugs market, by Country, 2015-2026 (USD Million)

TABLE North America Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE North America Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)

TABLE Europe Liver Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Europe Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Europe Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)

TABLE Asia Pacific Liver Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Asia Pacific Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Asia Pacific Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)

TABLE Latin America Liver Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Latin America Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Latin America Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)

TABLE Middle East and Africa Liver Cancer Drugs market, by country, 2015-2026 (USD Million)

TABLE Middle East and Africa Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Middle East and Africa Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)

# List Of Figures, Charts and Diagrams in Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

## List of Figures

FIGURE Liver Cancer Drugs market segmentation

FIGURE Market research methodology

FIGURE Value chain analysis

FIGURE Porter's Five Forces Analysis

FIGURE Market Attractiveness Analysis

FIGURE COVID-19 Impact Analysis

FIGURE Pre & Post COVID-19 Impact Comparison Study

FIGURE Competitive Landscape; Key company market share analysis, 2018

FIGURE Therapeutic Class segment market share analysis, 2019 & 2026

FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Targeted Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Immunotherapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Type segment market share analysis, 2019 & 2026

FIGURE Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hepatoblastoma segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hepatocellular Carcinoma segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Cholangio Carcinoma segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Regional segment market share analysis, 2019 & 2026

FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE North America Liver Cancer Drugs market share and leading players, 2018

FIGURE Europe Liver Cancer Drugs market share and leading players, 2018

FIGURE Asia Pacific Liver Cancer Drugs market share and leading players, 2018

FIGURE Latin America Liver Cancer Drugs market share and leading players, 2018

FIGURE Middle East and Africa Liver Cancer Drugs market share and leading players, 2018

FIGURE North America Liver Cancer Drugs market share analysis by country, 2018

FIGURE U.S. Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Canada Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Europe Liver Cancer Drugs market share analysis by country, 2018

FIGURE Germany Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Spain Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Italy Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE UK Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE France Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of the Europe Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Asia Pacific Liver Cancer Drugs market share analysis by country, 2018

FIGURE India Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE China Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Japan Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE South Korea Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Singapore Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of APAC Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin America Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin America Liver Cancer Drugs market share analysis by country, 2018

FIGURE Brazil Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Mexico Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Argentina Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of LATAM Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Liver Cancer Drugs market share analysis by country, 2018

FIGURE Saudi Arabia Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE United Arab Emirates Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)

# How to Buy...

Liver Cancer Drugs Market, By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/270616>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3250** | Single User Price
- \$4650** | Site License Price
- \$5650** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.